InFlectis BioScience-preview

Inflectisbioscience

InFlectis BioScience

Private

NantesHealthcare & Life Scienceshttps://inflectisbioscience.com

Last Round

Grant

Apr 30, 2024

Total Funding Raised

$9.5M

Company Overview

InFlectis BioScience is a clinical-stage biotechnology company that develops small molecule drugs intended to treat neuromuscular diseases by modulating the Integrated Stress Response (ISR).

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

small molecule therapiesneurodegenerative disease treatmentIntegrated Stress ResponseISRISR modulatoricerguastatAmyotrophic Lateral SclerosisALSCharcot-Marie-Tooth diseaseCMTMultiple SclerosisMSprotein misfoldingclinical-stage biotechdemyelinating disordersproteostasisoxidative stress

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

InFlectis BioScience Comps

Public and private peers based on sector, stage, and business model.

Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

InFlectis BioScience Funding Rounds

Historical fundraising activity

Round	Date	Amount Raised	Valuation	Investors	Sources
Grant	Apr 30, 2024
Grant	Jan 3, 2024
Strategic	Jun 22, 2021
Series A	Jun 1, 2016
Seed	Dec 3, 2014

View all Funding Rounds

Key People

Founding team and executive leadership

Pierre Miniou

Chief Operating Officer, Interim Chief Executive Officer

Executive Team

InFlectis BioScience Investors

Notable investors and investment history

Investor	Rounds
The ALS Association	Grant
Remiges Ventures	Series A
GO Capital	Series A, Seed
Crédit Mutuel Innovation	Series A

View all Investors

InFlectis BioScience Filings

SEC and related filings with document metadata.

Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

InFlectis BioScience Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about InFlectis BioScience's valuation, stock price, and market status.

Firmographic Details

HeadquartersNantes

Employee Range2

Year Founded2013

Last FundingApr 30, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.